To date, the most successful Nrf2 activator is DMF, which has been approved for the clinical treatment of relapsing-remitting multiple sclerosis [53] and for treatment of psoriasis [54]. This evidence concerns the gene NFE2L2 and relapsing-remitting multiple sclerosis.